JP5946454B2 - ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用 - Google Patents

ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用 Download PDF

Info

Publication number
JP5946454B2
JP5946454B2 JP2013526566A JP2013526566A JP5946454B2 JP 5946454 B2 JP5946454 B2 JP 5946454B2 JP 2013526566 A JP2013526566 A JP 2013526566A JP 2013526566 A JP2013526566 A JP 2013526566A JP 5946454 B2 JP5946454 B2 JP 5946454B2
Authority
JP
Japan
Prior art keywords
disease
composition
treatment
medicament
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013526566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536833A (ja
JP2013536833A5 (OSRAM
Inventor
パブロ ヴィジョスラダ，
パブロ ヴィジョスラダ，
アンヘル メセゲル，
アンヘル メセゲル，
Original Assignee
バイオニュア ファーマ， エセ．エレ．
バイオニュア ファーマ， エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオニュア ファーマ， エセ．エレ．, バイオニュア ファーマ， エセ．エレ． filed Critical バイオニュア ファーマ， エセ．エレ．
Publication of JP2013536833A publication Critical patent/JP2013536833A/ja
Publication of JP2013536833A5 publication Critical patent/JP2013536833A5/ja
Application granted granted Critical
Publication of JP5946454B2 publication Critical patent/JP5946454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2013526566A 2010-08-31 2011-08-31 ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用 Active JP5946454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37882310P 2010-08-31 2010-08-31
US61/378,823 2010-08-31
PCT/IB2011/002562 WO2012028959A1 (en) 2010-08-31 2011-08-31 Agonists of neurotrophin receptors and their use as medicaments

Publications (3)

Publication Number Publication Date
JP2013536833A JP2013536833A (ja) 2013-09-26
JP2013536833A5 JP2013536833A5 (OSRAM) 2014-10-09
JP5946454B2 true JP5946454B2 (ja) 2016-07-06

Family

ID=45048148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526566A Active JP5946454B2 (ja) 2010-08-31 2011-08-31 ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用

Country Status (19)

Country Link
US (3) US8791076B2 (OSRAM)
EP (1) EP2611775B8 (OSRAM)
JP (1) JP5946454B2 (OSRAM)
KR (1) KR101964954B1 (OSRAM)
CN (1) CN103270022B (OSRAM)
AU (1) AU2011298091B2 (OSRAM)
BR (1) BR112013004662B8 (OSRAM)
CA (1) CA2809774C (OSRAM)
DK (1) DK2611775T3 (OSRAM)
ES (1) ES2575684T3 (OSRAM)
HR (1) HRP20160553T1 (OSRAM)
HU (1) HUE029393T2 (OSRAM)
IL (1) IL224972A (OSRAM)
MX (1) MX340233B (OSRAM)
PL (1) PL2611775T3 (OSRAM)
PT (1) PT2611775E (OSRAM)
RU (1) RU2606622C2 (OSRAM)
SI (1) SI2611775T1 (OSRAM)
WO (1) WO2012028959A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190675A1 (ja) 2022-03-30 2023-10-05 ペプチドリーム株式会社 ＴｒｋＢ結合活性を有するペプチド複合体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
PT2611775E (pt) 2010-08-31 2016-06-07 Consejo Superior De Investig Científicas Agonistas dos recetores de neurotrofina e sua utilização como medicamentos
US20160193296A1 (en) * 2012-12-19 2016-07-07 Brown University Methods for treatment of microcephaly associated autism disorders
EP2950095B1 (en) * 2014-05-28 2018-08-29 Technische Universität Dresden Cell-based assay and screening methods for modulators of p75NTR signaling
US20190231787A1 (en) * 2016-08-25 2019-08-01 Pharmatrophix, Inc. Methods and compounds for treating alcohol use disorders and associated diseases
KR101821118B1 (ko) 2016-09-06 2018-01-23 가톨릭대학교 산학협력단 감보그 산(gambogic acid)을 포함한 알러지성 질환 예방 또는 치료용 조성물
CN107802823A (zh) * 2017-10-27 2018-03-16 胡军 Sh2b衔接蛋白1在治疗帕金森病中的功能应用
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
US11518763B2 (en) 2018-12-05 2022-12-06 Scohia Pharma, Inc. Macrocyclic compound and use thereof
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
WO2021046215A1 (en) * 2019-09-03 2021-03-11 Siekmeier Peter J Apparatuses and methods for identification and treatment of patients responsive to antipsychotic agent therapy
TW202131914A (zh) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案
TW202432095A (zh) * 2022-12-22 2024-08-16 瑞士商歐可麗營運有限公司 化合物、包含其的藥物組合物及其合成製程

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189214B (en) 1983-01-20 1986-06-30 Alkaloida Vegyeszeti Gyar,Hu Process for preparing pyrroline and pyrrolidine carboxamide derivatives
US6271205B1 (en) 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US5747458A (en) 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
DK1226127T3 (da) 2000-05-04 2009-10-19 Basf Se Substituerede phenylsulfamoylcarboxamider
ES2169690B1 (es) * 2000-10-06 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
ES2169691B1 (es) * 2000-10-11 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
US20050009847A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
WO2008040087A1 (en) 2006-10-06 2008-04-10 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and agents useful for same
EP1994944A1 (en) * 2007-05-21 2008-11-26 Laboratorios SALVAT, S.A. Polymer conjugate compounds for the inhibition of apoptosis
BRPI0919268B8 (pt) 2008-09-24 2021-05-25 Fujimoto Seiyaku Kk aptâmero que se liga ao ngf e medicamento
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf
EP2289882A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments
EP2289886A1 (en) 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
PT2611775E (pt) 2010-08-31 2016-06-07 Consejo Superior De Investig Científicas Agonistas dos recetores de neurotrofina e sua utilização como medicamentos

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190675A1 (ja) 2022-03-30 2023-10-05 ペプチドリーム株式会社 ＴｒｋＢ結合活性を有するペプチド複合体
KR20240168407A (ko) 2022-03-30 2024-11-29 페프티드림 아이엔씨. TrkB 결합 활성을 가지는 펩타이드 복합체

Also Published As

Publication number Publication date
IL224972A (en) 2015-05-31
EP2611775B8 (en) 2016-06-08
BR112013004662B1 (pt) 2021-09-28
KR101964954B1 (ko) 2019-04-03
JP2013536833A (ja) 2013-09-26
CN103270022B (zh) 2015-08-19
HRP20160553T1 (hr) 2016-09-23
US10106577B2 (en) 2018-10-23
CA2809774A1 (en) 2012-03-08
EP2611775B1 (en) 2016-03-16
DK2611775T3 (en) 2016-06-27
US20170121367A1 (en) 2017-05-04
US9453047B2 (en) 2016-09-27
PT2611775E (pt) 2016-06-07
EP2611775A1 (en) 2013-07-10
RU2606622C2 (ru) 2017-01-10
MX2013002329A (es) 2013-07-29
BR112013004662A2 (pt) 2016-08-02
PL2611775T3 (pl) 2016-11-30
KR20130106384A (ko) 2013-09-27
CA2809774C (en) 2019-03-05
ES2575684T3 (es) 2016-06-30
AU2011298091B2 (en) 2015-08-20
SI2611775T1 (sl) 2017-01-31
CN103270022A (zh) 2013-08-28
US20120052094A1 (en) 2012-03-01
WO2012028959A1 (en) 2012-03-08
AU2011298091A1 (en) 2013-04-18
US8791076B2 (en) 2014-07-29
MX340233B (es) 2016-07-01
RU2013113634A (ru) 2014-10-10
HUE029393T2 (en) 2017-03-28
US20150005239A1 (en) 2015-01-01
BR112013004662B8 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
JP5946454B2 (ja) ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
HK1258231A1 (zh) 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
JP2010528016A (ja) 細胞を刺激するための方法および組成物
RS53513B1 (sr) Glyx-13 za upotrebu u postupku tretiranja refraktornih depresija
CA2373416A1 (en) Method of inhibiting neurotrophin-receptor binding
US20250129054A1 (en) Prodrugs of 3,4-methylenedioxy-n-methcathinone and uses thereof
US20120237552A1 (en) Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments
JP2003503482A (ja) 環化アミノ酸誘導体
RS60957B1 (sr) Sinergistične kompozicije koje sadrže (r)-dimiracetam (1) i (s)-dimiracetam (2) u ne-racematnom odnosu
JP2007530509A (ja) 疼痛の処置のための１−［２ｈ−１−ベンゾピラン−２−オン−８−イル］−ピペラジン誘導体
WO2025249409A1 (ja) 髄鞘異常関連疾患治療剤の有効成分として有用な化合物
JP2018534366A (ja) 骨格筋の肥大剤としてのフロスタン−３オール誘導体
Sapronov et al. P. 6.046 Pharmacology of some new DL-aspartic acid derivatives
AU2023324882A1 (en) Benzazepine derivatives, compositions, and methods for treating cognitive impairment
Kulikova et al. P. 6.047 Regulatory system of brain chromatin in nootropic action
Ruiz et al. P. 6.045 Inhibitory effects of caffeine on cerebral blood flow. Evaluation by means of neurospect

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160324

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160531

R150 Certificate of patent or registration of utility model

Ref document number: 5946454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250